Zura Bio Limited (ZURA) Securities Investigation Notice – Levi & Korsinsky

Zura Bio Limited (ZURA) Securities Investigation Notice – Levi & Korsinsky

PR Newswire

ZURA shareholders saw their shares decline approximately 72% at market open after the Company disclosed that its Phase 2 TibuSHIELD trial of tibulizumab failed to meet its primary endpoint at either dose tested. Investors who took that loss may be eligible to seek a recovery as an investigation into potential securities law violations moves forward.

NEW YORK, Nov. 16, 2026 /PRNewswire/ — Zura Bio Limited (NASDAQ: ZURA) shares plunged approximately 72% at market open after the Company announced that its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa missed its Week 16 primary endpoint at both doses tested. Shareholders who suffered losses are encouraged to submit their loss details here . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP

The trial enrolled 247 participants. Its primary endpoint was the percent change from baseline in total abscess and inflammatory nodule count at Week 16, and it was not met at either dose. Key secondary endpoints were also missed. Zura Bio then discontinued development of tibulizumab in hidradenitis suppurativa.

Levi & Korsinsky is investigating potential securities law violations on behalf of affected ZURA investors.

If you lost money in the ZURA selloff, start your free loss review or call (212) 363-7500.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the ZURA Investigation

Q: How much did ZURA stock drop? A: Shares fell approximately 72% at the market open on November 9, 2026 after the Company disclosed that its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa did not meet its Week 16 primary endpoint and that it was discontinuing development in that indication. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: When did Zura Bio allegedly mislead investors? A: The investigation concerns statements made before the TibuSHIELD topline disclosure. The question is whether those statements allegedly caused investors to purchase securities at inflated prices.

Q: Who is eligible to participate in the ZURA investigation? A: Investors who purchased ZURA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What do ZURA investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my ZURA shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ZURA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis. Any attorneys’ fees and expenses are subject to court approval.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zura-bio-limited-zura-securities-investigation-notice—levi–korsinsky-302939309.html

SOURCE Levi & Korsinsky, LLP